EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 36 / No 11 (Novembre 2020) Med Sci (Paris), 36 11 (2020) 1034-1037 References
m/s / COVID-19
Free Access
Issue
Med Sci (Paris)
Volume 36, Number 11, Novembre 2020
m/s / COVID-19
Page(s) 1034 - 1037
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020203
Published online 05 November 2020
  1. Avis n° 2020.0025/AC/SEESP du 1er avril 2020 du collège de la Haute autorité de santé relatif au maintien de la vaccination des nourrissons dans le contexte de l’épidémie de COVID-19. Haute autorité de santé (HAS), 2020. https://www.has-sante.fr/jcms/p_3169084/fr/avis-n-2020-0025/ac/seesp-du-1er-avril-2020-du-college-de-la-haute-autorite-de-sante-relatif-au-maintien-de-la-vaccination-des-nourrissons-dans-le-contexte-de-l-epidemie-de-covid-19. [Google Scholar]
  2. Calendrier vaccinal des nourrissons et COVID-19. Paris : Académie Nationale de Médecine, 2020» http://www.academie-medecine.fr/wp-content/uploads/2020/04/Calendrier-vaccinal-des-nourrissons-et-COVID-19.pdf. [Google Scholar]
  3. Weill A, Drouin J, Desplas D, et al. Usage des médicaments de ville en France durant l’épidémie de Covid-19: point de situation après 5 semaines de confinement. Étude pharmaco-épidémiologique à partir des données de remboursement du SNDS. EPIPHARE rapport 2. Paris : ANSM, 2020. https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Usage-des-medicaments-en-ville-durant-l-epidemie-de-Covid-19-point-de-situation-apres-cinq-semaines-de-confinement-Point-d-information. [Google Scholar]
  4. Check Hayden E. Ebola obstructs malaria control. Nature 2014; 514 : 15–6. [Google Scholar]
  5. Nelson R. COVID-19 disrupts vaccine delivery. Lancet Infect Dis 2020; 20 : 546. [CrossRef] [PubMed] [Google Scholar]
  6. Macklin GR, O’Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 2020; 368 : 401–5. [Google Scholar]
  7. Roberts L. Polio vaccinators are back after pandemic pause. Science 2020; 369 : 360. [Google Scholar]
  8. Guiding principles for immunization activities during the COVID-19 pandemic. Interim guidance. Genève : WHO, 2020. [Google Scholar]
  9. Guha-Sapir D, Moitinho de Almeida M, Keita M, et al. COVID-19 policies: remember measles. Science 2020; 369 : 261. [Google Scholar]
  10. Roberton T, Carter ED, Chou VB, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. Lancet Glob Health 2020; 8 : e901–e8. [Google Scholar]
  11. Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19 :667–8. [CrossRef] [PubMed] [Google Scholar]
  12. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396 : 467–78. [CrossRef] [PubMed] [Google Scholar]
  13. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396 : 479–88. [CrossRef] [PubMed] [Google Scholar]
  14. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; doi.org/10.1016/S0140-6736(20)31866-3-. [Google Scholar]
  15. Abbott A. Researchers highlight questionable data in Russian coronavirus vaccine trial results. Nature 2020; 585 : 493. [Google Scholar]
  16. Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant Spike protein nanoparticle vaccine. N Engl J Med 2020; Doi:10.1056/NEJMoa2026920. [Google Scholar]
  17. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N Engl J Med 2020; doi: 10.1056/NEJMoa2022483. [Google Scholar]
  18. Pitard B.. Nanotaxi® pour les vaccins ARN et ADN. Med Sci (Paris) 2019 ; 35 : 749–752. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  19. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 12 August. [Google Scholar]
  20. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature 2020; 30 September. [Google Scholar]
  21. Bar-Zeev N, Moss WJ. Encouraging results from phase 1/2 COVID-19 vaccine trials. Lancet 2020; 396 : 448–9. [CrossRef] [PubMed] [Google Scholar]
  22. Vaidyanathan G. India will supply coronavirus vaccines to the world: will its people benefit? Nature 2020; doi: 10.1038/d41586-020-02507-x. [Google Scholar]
  23. https://www.covireivac.fr. [Google Scholar]
  24. Group C. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect Dis 2020; 20 : 769–70. [CrossRef] [PubMed] [Google Scholar]
  25. Expectations for a COVID-19 Vaccine. Chicago : Associated Press-NORC Center for Public Affairs Research, 2020. [Google Scholar]
  26. Caplan AL, Bateman-House AL. The danger of DIY vaccines. Science 2020; 369 : 1035. [Google Scholar]
  27. Stratégie de vaccination contre le COVID-19. Anticipation des scénarios possibles de vaccination et recommandations préliminaires sur les populations cibles. Saint-Denis : Haute Autorité de Santé (HAS), 2020. https://www.has-sante.fr/jcms/p_3197106/fr/strategie-de-vaccination-contre-le-covid-19-anticipation-des-scenarios-possibles-de-vaccination-et-recommandations-preliminaires-sur-les-populations-cibles. [Google Scholar]
  28. Barré-Sinoussi F, Atlani-Duault L, Muller S, et al. Vaccins contre le SARS-CoV-2. 9 juillet 2020. Une stratégie de vaccination. Paris : Ministère des solidarités et de la santé, 2020. https://solidarites-sante.gouv.fr/IMG/pdf/avis_vaccins_9_juillet_2020_-_care_-_conseil_scientifique_-_comite_vaccin.pdf. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.